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Fc receptor-like (FCRL) 1–5 molecules are exclusively expressed
in B-cells and have recently been considered as potential targets
for immunotherapy of B-cell malignancies. In this study, the
expression pattern of FCRL1–5 molecules was investigated in Ira-
nian patients with B-cell chronic lymphocytic leukemia (B-CLL).
Our RT-PCR results have demonstrated that all FCRL molecules,
except FCRL4, were expressed in the vast majority of the patients
with B-CLL. However, comparison of the relative mRNA expres-
sion levels of FCRL between B-CLL (n 5 86) and elderly normal
subjects (n 5 10) revealed significantly lower expression levels of
FCRL1 (p < 0.0001), FCRL3 (p 5 0.01) and FCRL4 (p 5 0.002),
but not FCRL2 or FCRL5, in cases with B-CLL. No significant
differences were observed between the indolent and progressive
subtypes of patients with B-CLL. Comparison between the
mutated and unmutated subtypes revealed a significantly higher
expression level of FCRL3 (p 5 0.017) in patients with mutated
CLL. Surface and intracytoplasmic expression of FCRL1, 2, 4 and
5 in leukemic cells of 12 patients by flow cytometry revealed simi-
lar results to those obtained by RT-PCR with a few exceptions.
Thus, while FCRL4 was expressed in only 2 samples at intracyto-
plasmic level, FCRL1 and 2 were expressed in the majority of
samples, both at surface and intracytoplasm. FCRL5 protein was
also detected in 10 samples, but surface expression was confirmed
in only 2. Analysis of B-cells from 5 normal subjects by flow
cytometry revealed higher expression levels of FCRL molecules
compared to CLL. Our results indicate differential expression of
FCRL molecules in B-CLL and suggest the potential implication
of FCRL1 and 2 for immunotherapeutic interventions.
' 2008 Wiley-Liss, Inc.
Key words: FCRL; CLL; RT-PCR; flow cytometry
Recently identified Fc receptor-like (FCRL) molecules,1,2 previ-
ously known as Fc receptor homolog (FcRH),3 immunoglobulin
superfamily receptor translocation associated (IRTA),4 immuno-
globulin superfamily-Fc receptor-gp 42 (IFGP),5 SH2 domain-
containing phosphatases anchor protein (SPAP)6 and anti-IgM
activating sequence (BXMAS),7 are exclusively expressed in B-
cell lineage, with the exception of one member of the family
(FCRL6), which is mainly expressed in T and NK cells.8 Owing to
the presence of immunoreceptor tyrosine-based activating/inhibi-
tory motifs (ITAM/ITIM) in their cytoplasmic region,9 some
immunomodulatory roles have been attributed to these molecules.
FCRL1 may act as activating coreceptor on B cells,10 whereas
FCRL4 can potently inhibit B cell receptor signaling.11 mRNA
expression analysis in normal B cells indicates that FCRL1 and
FCRL2 are highly expressed in na€ıve B cells.12 In contrast,
FCRL3 and FCRL5 are predominantly expressed in centrocytes
and postgerminal center (GC) cells.12 FCRL4 transcripts are
exclusively detected in memory B cells.11,12 FCRL3 molecule has
also been localized on marginal zone B-cells as well as B1 cells,
both of which are implicated in T-cell-independent antibody
response.13
Several studies have recently investigated the expression pattern
of FCRL molecules in a variety of B-cell malignancies.4,7,8,14,15
Secretory form of FCRL5, also known as soluble CD307, has
been shown to be elevated in the blood of patients with CLL, mul-
tiple myeloma (MM) and mantle cell lymphoma (MCL), and its
level was correlated with tumor burden.16
Limited reports have so far been published regarding the
expression profile of FCRL family members in the leukemic cells
of B-cell chronic lymphocytic leukemia (B-CLL). Initial studies
were conducted employing the microarray methodology.17
Expression of FCRL molecules at protein level has recently been
studied by immunocytochemistry or flow cytometry.15,16,18 Com-
parative analysis of FCRL expression at mRNA and protein levels
has not been studied yet. Meanwhile, all published data has been
derived from studies conducted on Western populations. In the
present study, the expression profile of FCRL1–5 molecules was
investigated for the first time in 86 Iranian patients with progres-
sive or indolent B-CLL by RT-PCR. Protein expression of these
molecules was also studied both at surface and intracytoplasmic
levels in 12 patients and 5 normal subjects by flow cytometry.
Material and methods
Patients and controls
Heparinized peripheral blood was collected from eighty-six Ira-
nian patients with CLL attending the Oncology Clinics of Vali-
Asr and Firozgar Hospitals, affiliated to Medical Sciences/Univer-
sity of Tehran and Iran University of Medical Sciences, respec-
tively. A consent letter was taken from all patients and the study
was approved by the Ethical Committee of Medical Sciences/ Uni-
versity of Tehran. The patients were clinically categorized in indo-
lent (n 5 41), progressive (n 5 38) and newly diagnosed (n 5 7)
subtypes. Twenty-one patients were under treatment of 6 months
to 3 years before the time of sampling. Disease progression was
identified on the basis of either of the following criteria: lympho-
cyte count doubling time of less than 1 year; progression to a
more advanced Rai stage; development of systemic symptoms; de-
velopment of Richter’s syndrome; downward trend of hemoglobin
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(Hb) concentration or platelet count to below the normal range
(Hb < 13.5 g/dl for males and <11.5 g/dl for females; platelet
count < 150 3 109/l) even when not meeting the criteria for stage
III or IV disease (Hb < 10 g/dl; platelet count < 1003109/l). Pos-
session of one of these characteristics was sufficient to qualify as
progressive disease.19 Nucleotide sequence analysis of the immu-
noglobulin variable region heavy chain (IgVH) of the leukemic
cells has allowed classification of the patients into mutated (n 5
55) and unmutated (n 5 31) groups, based on the presence of
more than 2% mutation rate.20 Major demographic features of all
cases with CLL have been shown in supplementary Table 1. Ten
elderly normal subjects (mean age 60 years) were also included to
determine normal cut-off levels of FCRL mRNA expression. Pe-
ripheral blood mononuclear cells (PBMCs) of all subjects were
isolated by density-gradient centrifugation using Histopaque
(Sigma, St. Louis, MO). RNA extraction and cDNA synthesis
were performed as previously described.21
Isolation of B- and T-cells from PBMC by magnetic
bead separation
B- and T-cells were isolated from peripheral blood of 5 normal
subjects using MACS negative selection kits (Miltenyi Biotec,
Bergisch Gladbach, Germany) according to the manufacturer’s
instructions. Briefly, PBMCs were isolated and CD19þ and CD3þ
cells were enriched by negative selection method using MACS
microbeads and midiMACS columns. The purity of cells were
>95% as determined by flow cytometry.
Polymerase chain reaction
Amplification of FCRL1–5 and b-actin mRNA was performed
using specific primers listed in Table I. Twenty-five-microliter
reaction mixture of PCR was prepared using 2.5 ll 103 PCR
buffer, 3.5 ll (for b-actin) and 1 ll (for FCRL1 and 4) or 1.5 ll
(for FCRL2, 3, and 5) 25 mM MgCl2, 1.5 ll 10 mM dNTPs, 1 ll
each primer (10 pmol/ll), 0.2 ll Taq-DNA polymerase (10 U/ll)
(CinnaGen, Tehran, Iran) and 1 ll template cDNA. Each amplifi-
cation reaction underwent initial denaturation at 94C for 5 min
followed by 39 cycles of denaturation at 94C for 30 sec, anneal-
ing at 60C (for FCRL2 and b-actin) or 62C (for FCRL1, 3–5)
for 30 sec, extension at 72C for 1 min and final extension at
72C for 10 min. Amplified products were visualized in 1.5%
agarose gel containing ethidium bromide and documented with
gel documentation system (UVP, CA, USA). Amplicon sizes
were 793, 430, 890, 686 and 768 base pairs for FCRL1–5, respec-
tively. Burkitt’s lymphoma cell lines were used as positive con-
trols for amplification of FCRL1, 3, and 5 (Ramos), FCRL2
(BL41) and FCRL4 (Raji). The densities of FCRLs and b-actin
PCR product bands were determined by Labworks 4.0 software
(UVP, CA), and the ratio of the two bands was calculated for
each sample, as follows: (density of FCRL band/b-actin density
band) 3 100.
Indirect immunoflourescence
The staining was performed on PBMCs from 12 patients with
CLL and 5 normal controls at both surface and intracytoplasmic
levels. After separation of the PBMCs and twice washing with
washing buffer (PBS 0.15 M, 0.5% BSA, 0.1% NaN3), 10
6 cells
were incubated with 2.5 lg/ml of biotinylated goat antihuman
FCRL1, FCRL2, FCRL4 and FCRL5 antibodies (R&D Systems,
Minneapolis, MN) as primary antibodies for 45 min. Biotinylated
goat antihuman Ig and biotinylated unimmunized goat IgG (pre-
pared in our laboratory) were also included as positive and nega-
tive controls, respectively. For intracytoplasmic staining, the cells
were initially fixed with 2% paraformaldehyde in PBS (0.15 M,
0.1% NaN3) for 10 min and, after twice washing, were incubated
with permeabilizing solution (Beckton Dickinson, CA) for 10 min.
Afterwards, the cells were washed twice with washing buffer and
incubated with appropriate dilution of primary antibody. After
incubation, the cells were washed twice with washing buffer and
then incubated with RPE-conjugated streptavidin (DAKO,
Glostrup, Denmark) as detector, for 45 min. Cells were then
washed twice before scanning by flow cytometer (Partec, Nurem-
berg, Germany). Double staining of B cells from 5 normal subjects
and 2 CLL patients was performed using FITC-CD19 monoclonal
antibody (clone HD37, Cytomation; Dako Corp, Glostrup, Den-
mark) and biotinylated anti-FCRL Abs to determine the frequency
of FCRL-expressing B cells. To calculate relative expression lev-
els, mean fluorescence intensity (MFI) was determined by subtrac-
tion of the MFI of the antigen-specific fluorochrome-conjugated
Abs from the MFI of the irrelevant fluorochrome-conjugated iso-
type-matched negative control. Data analysis was performed using
Flomax flow cytometry analysis software (Partec, Nuremberg,
Germany). Background staining with the biotinylated unimmu-
nized goat IgG was used to eliminate nonspecific binding of the
goat anti-FCRL antibodies.
Statistical analysis
Statistical analyses of the results were performed using Pearson
Correlation, Chi-Square, student’s t test, and Mann–Whitney U
tests as appropriate. Analyses were conducted using the SPSS sta-
tistical package (SPSS, Chicago, IL). p-values of less than 0.05
were considered significant.
TABLE I – LIST OF SPECIFIC PRIMERS USED FOR AMPLIFICATION OF FCRL AND b-ACTIN GENES
Gene name Primer sequence Amplicon size (bp)
FCRL1
F 50-CTC AAC TTC ACA GTG CCT ACT GGG-30 793
R 50-TCC TGC AGA GTC ACT AAC CTT GAG-30
FCRL2
F 50-CCA GTG TAT GTC AAT GTG GGC TCTG-30 430
R 50-CAT TCT TCC CTCAAATCT TTA CAC-30
FCRL3
F 50-CAG CAC GTG GAT TCG AGT CAC-30 890
R 50-CAG ATC TGG GAA TAA ATC GGG TTG-30
FCRL4
F 50-TCT TCA GAG ATG GCG AGG TCA-30 686
R 50-TTT TGG GGT GTA CAT CAA CAT ACAAC-30
FCRL5
F 50-TGT TGC CCT GTT TCT TCCAAT ACA-30 768




F: forward primer; R: reverse primer.
2114 KAZEMI ET AL.
Results
FCRL1–5 mRNA expression
Qualitative expression of FCRL1–5 mRNA was determined in
patients with B-CLL and normal controls by visualization of the
corresponding PCR product following electrophoresis. Represen-
tative RT-PCR results obtained for a number of patients are illus-
trated in Figure 1. Our results showed expression of FCRL1–3 and
5 molecules in 91–100% of patients, with no significant differen-
ces between patients with B-CLL and normal elderly controls.
FCRL4, however, was less frequently expressed in different
groups of patients compared to normal subjects (p < 0.05) (Table
II). Relative expression of FCRL1–5 mRNA levels in patients and
normal subjects was determined by calculation of the ratio of
FCRL PCR product band density to that of b-actin. Comparison
of the expression levels of these molecules in PBMC obtained
from CLL and normal elderly subjects demonstrated significant
down-regulation of FCRL1 (p < 0.0001), FCRL3 (p 5 0.01) and
FCRL4 (p 5 0.002) in cases with CLL (Table III and Fig. 2a).
FCRL2 and 5, however, were similarly represented in patients
with CLL and normal controls.
Relative mRNA expression levels of all FCRL genes were also
determined in purified B-cell and T-cells isolated by magnetic
beads from PBMC of 5 normal subjects. Representative results are
shown in Figure 1. Expression of FCRL molecules was exclu-
sively detectable in B-cells with no or negligible expression in the
isolated T-cells population.
No significant differences were observed for any of the FCRL
molecules between progressive and indolent patients and also
between these 2 groups and patients undergoing treatment
(treated patients with CLL) (Table III). A similar expression pat-
tern was also observed in patients with CLL with mutated and
unmated VH regions, with the exception of FCRL3, which was
expressed at higher levels in mutated patients (p 5 0.017) (Table
III and Fig. 2b).
Intracytoplasmic and surface expression of FCRL protein
Flow cytometric analysis of surface and intracytoplasmic
expression of FCRL1, FCRL2, FCRL4, and FCRL5 molecules
was performed in leukemic cells from 12 patients with CLL (6
progressive, 5 indolent and 1 newly diagnosed patients). Ten
PBMC samples were tested by single-staining using biotinylated
FCRL polyclonal antibodies, and 2 samples were analyzed by
double-staining using FITC-CD19 MAb and biotinylated FCRL
polyclonal antibodies. FCRL3-specific antibody was not available
for this study. Representative results obtained for 2 patients and 2
normal subjects are illustrated in Figure 3. Overall, the protein
expression pattern was similar to that obtained by RT-PCR, with
a few exceptions (Table IV). Thus, while FCRL4 was positive in
only 2 out of 12 samples at intracytoplasmic level, FCRL1 and
FCRL2 were expressed in 11/12 and 9/12 cases, respectively, in
most cases at both surface and intracytoplasmic levels. FCRL5
molecule was also detected in 10/12 cases, but surface expression
was confirmed in only 2 samples, both of which displayed
mutated VH and indolent disease (Table IV). Expression of
FCRL protein was studied in B-cells of 5 normal subjects by dou-
ble-staining of PBMC using FITC-CD19 MAb and biotinylated
FCRL antibodies detected by RPE-streptavidin. Representative
results are illustrated in Figure 3. FCRL1, 2, 4 and 5 molecules
were detected at both surface and intracytoplasm of B-cells from
all subjects, with the exception of 1 sample being negative for
FCRL4 (Table V). Comparison of mean fluorescence intensity
(MFI) obtained for all FCRL molecules, both at surface and intra-
cytoplasm, showed a significantly higher MFI for FCRL1, 2 and
FIGURE 1 – Representative RT-PCR results of FCRL1–5 genes
expression in patients with CLL and normal subjects. B and T refer to
purified B- and T-lymphocytes isolated from PBMC by magnetic
beads separation.
TABLE II – FREQUENCY OF FCRL1–5 EXPRESSION IN IRANIAN PATIENTS WITH B-CLL AND ELDERLY NORMAL SUBJECTS
FCRL Normal (n 5 10) All CLL
(n5 86)
Progressive











FCRL1 10 (100) 82 (95) 37 (97.4) 39 (95.1) 53 (96.4) 29 (93.5) 21 (100) 61 (93.8)
FCRL2 6 (60) 81 (94) 37 (97.4) 39 (95.1) 52 (94.5) 29 (93.5) 21 (100) 60 (92.3)
FCRL3 10 (100) 78 (91) 36 (94.7) 36 (87.8) 51 (92.7) 27 (87.1) 19 (90.5) 59 (90.8)
FCRL4 7 (70) 16 (19) 5 (13.2) 11 (26.8) 11 (20) 5 (16.1) 6 (28.6) 10 (15.4)
FCRL5 10 (100) 86 (100) 38 (100) 41 (100) 55 (100) 31 (100) 21 (100) 65 (100)
The results represent number (percent) of positive cases based on visualization of amplified PCR product of the specified FCRL genes.

















FCRL1 184 (71) 103 (71)* 103 (56) 109 (57) 109 (56) 93 (54) 108 (63) 102 (53)
FCRL2 42 (51) 67 (51) 73 (57) 66 (44) 68 (50) 64 (51) 71 (56) 62 (47)
FCRL3 116 (51) 72 (51)* 71 (41) 76 (60) 82 (55) 53 (37)* 77 (63) 71 (47)
FCRL4 15 (15) 6 (14)* 4 (12) 9 (17) 6 (15) 5 (13) 8 (14) 6 (15)
FCRL5 122 (47) 117 (40) 120 (38) 118 (41) 121 (40) 109 (40) 127 (55) 113 (33)
The results represent the mean (standard deviation) ratio of FCRL PCR product band density to that of b-actin multiplied by 100.
*Comparison between all patients with CLL with normal subjects revealed significant differences for FCRL1 (p < 0.0001), FCRL3 (p 5
0.01) and FCRL4 (p 5 0.002). No significant differences were observed for any of the FCRL molecules when progressive, indolent and
untreated; treated patients with CLL were compared with each other, with the exception of FCRL3, which was expressed at significantly higher
levels in mutated compared to unmutated patients (p 5 0.017).
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5 as well as immunoglobulin in normal subjects compared to
patients with CLL (Table VI).
Discussion
In the present study, we have demonstrated the expression of
FCRL1–3 and 5, but not FCRL4 mRNA in the majority of our B-
CLL samples. However, comparison of the FCRL mRNA expres-
sion level in PBMCs of the patients with that of the normal elderly
subjects revealed a significant down-regulation of FCRL1, 3 and
4, but not FCRL2 or 5 in the patients. Consistent with its lack of
expression on circulating normal B-cells,14,22 FCRL4 could not be
appreciably detected in leukemic cells from the majority of our
patients with B-CLL (Tables II, III).
There are some important methodological issues regarding our
semiquantitative RT-PCR assay and the source of cells isolated
from patients and normal subjects, which need special considera-
tion. In this study, representation of FCRL expression as a ratio to
the housekeeping gene b-actin was intended to normalize the
data and avoid variations due to differences in cDNA concentra-
tion or loading different amounts of PCR product on the electro-
phoresis gel. Further caution was exercised by simultaneous elec-
trophoresis of FCRL and b-actin PCR products for each subject
on the same gel. This would minimize variations due to technical
shortcomings. The other important issue is the difference of the
source of cells collected from patients and controls. Although,
PBMCs were collected from peripheral blood of both groups of
subjects, the PBMCs isolated from patients with B-CLL were pre-
dominantly (60–90%) leukemic B-cells (supplementary Table 1),
whereas only 10–20% of the PBMCs isolated from normal sub-
jects are B-cells. Therefore, comparison of FCRL mRNA expres-
sion in these 2 groups of subjects may not be appropriate. How-
ever, since constitutive expression of FCRL1–5 molecules is re-
stricted to B-cells and other blood cells are totally
negative3,4,10,13,15,22 with the exception of FCRL3, which is also
expressed in NK and T-cells,10,13,15 it appears that the significant
down-regulation of FCRL1, 3 and 4 observed in our study would
have been more magnified and signified if pure B-cells could
have been isolated from the normal subjects and tested. Employ-
ment of PBMCs from normal subjects reduces the PCR product
band densities of FCRL molecules to that of b-actin for each sam-
ple tested. Thus, much higher significant differences are expected
if pure normal B-cells are employed and compared for FCRL
mRNA expression with leukemic CLL B-cells. This is clearly
indicated in our results obtained in isolated B- and T-cells from a
limited number of normal subjects showing higher expression of
FCRL mRNA levels in B-cells compared to T-cells, which are
essentially negative (Fig. 1).
Initial studies using cDNA clones present on the lymphochip
microarray demonstrated up-regulation of FCRL1–4 in B-CLL, as
well as diffuse large B-cell lymphoma and follicular lymphoma.17
At protein level, surface membrane expression of FCRL1–5 fam-
ily members was examined in leukemic CLL B-cells by flow
cytometry using monoclonal antibodies.15 The expression pattern
was reported to be similar to that of the normal mature peripheral
B-cells, with the exception of FCRL3, which was significantly up-
regulated in patients with B-CLL. Of the B-CLL cases tested, leu-
kemic cells from 15/15, 15/20, 14/20, 1/20 and 14/15 of the sub-
jects displayed FCRL1–5, respectively.15 Membrane expression of
FCRL1 and FCRL516,18 and FCRL1–5 molecules has also been
investigated separately in 2 other recent studies by flow cytometry.
The results presented in these 2 papers showed that 12/14 and 23/
29 of the CLL samples tested were positive for FCRL1 and
FCRL5, respectively.
Overall, our flow cytometry results are similar to those obtained
from previous studies (mentioned above). Of the 12 randomly
selected cases with B-CLL tested, 11/12, 9/12, 2/12 and 10/12
were found to express FCRL1, FCRL2, FCRL4 and FCRL5 mole-
cules, respectively (Table IV). We could not study FCRL3 mole-
cule at protein level because of unavailability of the antibody. De-
spite the overall similarity observed in our study and previous
reports regarding the frequency of FCRL protein expression,
FCRL5 was detected only in the cytoplasm, but not on surface
membrane of the leukemic cells in the majority of our patients.
Surface staining was observed in only 2/12 samples studied. Lack
of surface expression of FCRL5 in our patients does not seem to
be associated to ethnicity of the patients, because B-cells from all
5 normal subjects studied by flow cytometry displayed the mem-
brane-bound FCRL5 molecule (Table V). Rather it may reflect the
weak reactivity of the antibody in flow cytometry technique as
well as the lower expression level of this molecule at the surface
of the leukemic cells, which renders them undetectable by the
weak polyclonal antibody employed in this study. Significantly
higher MFI of FCRL5 in normal B-cells confirms our proposition.
Accumulation of FCRL5 in the cytoplasm would naturally result
in quantitatively higher expression levels compared to the mem-
brane-bound form of this molecule. The anti-FCRL antibodies
employed in our study are all polyclonal antibodies with potential
cross-reactivity to other members of the FCRL family. However,
as indicated by the supplier (R&D Co.), apart from the anti-
FCRL1 Ab, which shows minor (25%) cross-reactivity with
recombinant human FCRL2 molecule, none of the other Abs
FIGURE 2 – Distribution of FCRL1–5 mRNA levels in PBMC from
different groups of patients with CLL and normal elderly subjects.
The results are expressed as the ratio of FCRL to b-actin PCR product
band density in (a) all patients with CLL and elderly normal subjects
and (b) different subtypes of patients with CLL. Comparison of the
relative expression levels of FCRL1–5 of all subjects with CLL and
elderly normal subjects demonstrated significant down-regulation of
FCRL1 (p < 0.0001), FCRL3 (p 5 0.01), and FCRL4 (p 5 0.002) in
cases with CLL. FCRL2 and 5 were similarly represented in patients
with CLL and normal controls. No significant differences were
observed between indolent, progressive, mutated and unmutated
groups of patients with the exception of FCRL3, which was expressed
at higher level in mutated compared to unmutated patients (p 5
0.017). PBMC, peripheral blood mononuclear cells. [Color figure can
be viewed in the online issue, which is available at www.interscience.
wiley.com.]
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cross-react with human FCRL proteins. The cross-reactivity of the
other Abs has been stated to be less than 2–5%, which is essen-
tially negligible.
In previous flow cytometry studies, 1/15 and 6/29 of the cases
with B-CLL tested were found to be negative for membrane-
bound FCRL5.15,16 Intracytoplasmic staining was not reported in
these articles. This discrepancy could be attributed to the specific-
ity of the antibodies employed in these studies or transcription of
different forms of FCRL5 in different groups of patients with dif-
ferent ethnic backgrounds. FCRL5 has been proposed to have
2 membrane-bound and 1 secretory forms.16 High levels of soluble
FCRL5 (also known as CD307) were detected in serum of a large
number of patients with B-CLL.16 It would be interesting to quan-
titate soluble FCRL5 level in serum of our patients to find out any
correlation with the membrane-bound or intracytoplasmic expres-
sion pattern detected by flow cytometry. Quantitation of soluble
FCRL5 molecule might also be valuable to differentiate between
indolent and progressive B-CLL clinical subtypes, because the
level of soluble FCRL5 was associated to WBC count and disease
burden in patients with CLL.16
Chronic lymphocytic leukemia follows an extremely variable
clinical course with overall survival times ranging from months to
decades.23 Immunoglobulin variable region heavy chain (IgVH)
mutational status separates CLL into 2 different forms of the dis-
ease, mutated and unmutated forms, which are closely associated
to the indolent and progressive clinical courses, respectively.20,24
In an attempt to large scale genotyping of CLL using microarray
technology, however, it has been shown that CLL displays a com-
FIGURE 3 – Representative flow cytometry results of FCRL protein expression in a number of patients with CLL and normal subjects. Values
presented in each figure represent percent of positive cells. Biotinylated goat IgG and biotinylated goat antihuman immunoglobulin were used as
negative (NC) and positive controls (PC), respectively. S, surface expression; IC, intracytoplasmic expression.
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mon characteristic gene expression profile that is largely independ-
ent of their IgVH genotype.25,26 Our results appear to follow a sim-
ilar pattern with no significant differences for any of the FCRL
molecules between indolent and progressive patients, though
FCRL3 mRNA levels were expressed at higher levels in mutated
compared to unmutated patients (p 5 0.017) (Tables II, III). More
studies need to be performed to assess and extend our findings.
Since a number of our patients, mostly from the progressive
group, have already been treated before the time of sampling,
these patients were classified in a separate group and compared
with indolent, progressive and newly diagnosed patients for the
frequency of FCRL mRNA expression. We found no significant
difference between these groups of patients, suggesting lack of
effect of previous treatment on FCRL expression in leukemic CLL
B-cells. This is also inferred from the high percentage of lympho-
cytosis, mostly with leukemic origin, observed in treated patients
despite a substantial decrease in WBC count in a number of these
patients (supplementary Table 1).
No RT-PCR results have so far been published regarding FCRL
expression in progressive and indolent patients with B-CLL to be
able to compare them with our results. Initial microarray studies
have identified FCRL2 and 3 to be associated to the indolent dis-
ease.17 Comparison of flow cytometry results in a limited number
of patients has recently demonstrated a significantly higher mean
fluorescence intensity only for FCRL2 molecule in progressive
patients compared to the indolent group.15 We have not been able
to perform statistical analysis on our flow cytometry results due to
the small sample size of the progressive and indolent samples
checked by flow cytometry, though the frequency and intensity of
expression of all FCRL molecules tested were overall similar in
these 2 groups of patients (Table IV).
Comparing CLL genetic profile with those of purified normal B
cell populations indicated that the common CLL profile is more
related to memory B cells than to those derived from na€ıve B cells,
CD5þ B cells and germinal center centroblasts or centrocytes.25
Expression of CD27 in leukemic B-cells of the majority of patients
with CLL suggests a memory phenotype for these cells.27 This prop-
osition, however, does not seem to fit with the lack of expression of
FCRL4 molecule in the majority of our patients with CLL and also
TABLE IV – SURFACE AND INTRACYTOPLASMIC EXPRESSION OF FCRL1, 2, 4, AND 5 MOLECULES IN FRESH







NC PC FCRL1 FCRL2 FCRL4 FCRL5
S IC S IC S IC mRNA S IC mRNA S IC mRNA S IC mRNA
CLL8 P M 2 2 þþþþ þþþþ 2 þ þ 2 2 þ 2 2 2 2 2 þ
CLL10 I U 2 2 þþþþ þþþþ þ NT þ NT 2 2 2 2 2 2 þ þ
CLL13 I M 2 2 þþ þþþþ þ þþþ þ þþþ þ þ 2 2 2 þþ þþ þ
CLL14 P M 2 2 þþþ þþþþ þ þ þ þþ NT þ 2 2 þ 2 þ þ
CLL15 I M 2 2 þþ þþþþ þþ þþþ þ þþþþ þþþ þ 2 NT 2 þþ þþþþ þ
CLL20 I M 2 2 þþ þþþþ 2 2 þ 2 2 þ 2 2 2 2 2 þ
CLL23* ND U 2 2 þþþþ þþþþ þþþþ þþþþ þ þþþ þþ þ 2 þ 2 2 þ þ
CLL33 P M 2 2 þþþ þþþþ þþþ þþþþ þ þþþ þþ þ 2 2 2 2 þþþ þ
CLL62 P U 2 2 þþ þþþ 2 þ þ 2 þ þ 2 þ þ 2 þ þ
CLL63* P U 2 2 þþþþ þþþþ þþþ þþþ þ þþ NT þ 2 2 2 2 þ þ
CLL64 P M 2 2 þþþþ þþþþ þþ þ þ þþ NT þ 2 2 2 2 þ þ
CLL66 I M 2 2 þþþþ þþþþ þþþ þþþþ þ þþþ þþþ þ 2 2 þ 2 þþþ þ
The flow cytometry results are presented as follows: 0–10% 5 2; 10–20%5 þ; 20–40% 5 þþ; 40–60%5 þþþ; >60% 5 þþþþ.
I, indolent; P, progressive; U, unmutated; M, mutated; S, surface; IC, intracytoplasmic; NC, negative control (biotinylated unimmunized goat
IgG); PC, positive control (biotinylated goat antihuman immunoglobulin); NT, not tested; ND, newly diagnosed.
*CLL23 and CLL63 samples were analyzed by double staining of PBMC cells using FITC-CD19 MAb and biotinylated RPE-labelled anti-
FCRL antibodies; all other samples were single stained with the FCRL-specific antibodies.
TABLE V – SURFACE AND INTRACYTOPLASMIC EXPRESSION OF FCRL1, 2, 4, AND 5 MOLECULES IN CD19þ B CELLS OF NORMAL
SUBJECTS BY FLOW CYTOMETRY
Normal
subjects
NC PC FCRL1 FCRL2 FCRL4 FCRL5
S IC S IC S IC S IC S IC S IC
N1 – – þþþþ þþþþ þþþþ þþþþ þþþþ þþþ þ þ þþþ þþ
N2 – – þþþþ þþþþ þþþþ þþþþ þþþþ þþþþ þ þþ þþ NT
N3 – – þþþþ þþþþ þþþþ þþþþ þþþ þþþ – þþ þ þþ
N4 – – þþþþ þþþþ þþþþ þþþþ þþþþ þþþ þþ þþ þþ þþ
N5 – – þþþþ þþþþ þþþþ þþþþ þþþþ þþþ þþ þþ þþ þþþ
Double staining was performed on PBMC using FITC-CD19 MAb and biotinylated RPE-labelled anti-FCRL antibodies.
The flow cytometry results are presented as follows: 0–10% 5 –; 10–20% 5 þ; 20–40%5 þþ; 40–60%5 þþþ; >60%5 þþþþ.
S, surface; IC, intracytoplasmic; NC, negative control (biotinylated unimmunized goat IgG); PC, positive control (biotinylated goat antihuman
immunoglobulin); NT, not tested.
TABLE VI – COMPARISON OF MEAN FLUORESCENCE INTENSITY (MFI) OF
SURFACE AND INTRACYTOPLASMIC FCRL AND IMMUNOGLOBULIN
EXPRESSION BETWEEN PATIENTS WITH CLL AND NORMAL CONTROLS
Molecule CLL (n5 12) Normal (n 5 5) p value
FCRL1
S 0.65 (0.54) 7.5 (0.7) 0.001
IC 0.73 (0.6) 4.0 (0.5) 0.001
FCRL2
S 0.77 (0.6) 4.7 (2.0) 0.002
IC 0.75 (1.2) 5.9 (1.6) 0.002
FCRL4
S – 1.8 (0.4) –
IC 0.93 (0.9) 2.5 (1.4) 0.190
FCRL5
S 0.22 (0.3) 2.3 (0.69) 0.095
IC 0.64 (0.6) 2.1 (0.9) 0.008
Ig
S 2.6 (2.4) 70.2 (7.7) <0.0001
IC 6.3 (4.3) 69.2 (12) <0.0001
The results represent mean (SD) fluorescence intensity calculated
by subtraction of the MFI of the FCRL or human immunoglobulin-
specific fluorochrome-conjugated antibodies from the MFI of the irrel-
evant fluorochrome-conjugated isotype-matched negative control anti-
bodies.
S, surface; IC, intracytoplasmic; Ig, immunoglobulin.
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those reported by other investigators.15 FCRL4 is considered as a B-
cell memory marker.11 The B-CLL cells, therefore, may originate
from the recently identified FCRL4 negative memory pool.22
Altogether, our results confirm and extend previous studies indi-
cating differential expression of FCRL molecules in B-CLL. The
profile of expression of FCRL molecules was similar between pro-
gressive and indolent patients. A similar expression pattern was
also observed in mutated and unmutated groups of patients, with
the exception of FCRL3, which was expressed at higher levels in
mutated patients. Contrary to previous findings, expression of
FCRL5 protein was confined to the cytoplasm of the leukemic
cells in the majority of the patients. This observation may argue
against selection of this molecule for targeted immunotherapy of
B-CLL, which has previously been proposed by some investiga-
tors.15,16 FCRL1 and to a lesser extent FCRL2, which are widely
expressed in B-CLL cells, both as membrane-bound and intracyto-
plasmic forms, seem to be more suitable targets for such therapeu-
tic interventions, as already suggested by others.15,18
Note added in proof: During resubmission of the revised ver-
sion of this manuscript, we noticed the article of Li et al. published
online in the most recent issue of Blood describing the expression
profile of FCRL1–5 molecules at protein level in IgVH mutated
and unmutated forms of B-CLL.28 Contrary to our findings of sig-
nificantly higher expression level of only FCRL3 in mutated sam-
ples at mRNA level, they reported increased expression of
FCRL1–3 and 5, more significantly FCRL2, in the mutated group
of patients compared to unmutated samples. They also reported a
similar expression level of all FCRL molecules in leukemic B-
cells of patients with CLL and polyclonal B-cells of normal sub-
jects, which contradicts our results. These discrepancies could be
due to ethnic differences between the subjects studied in these
2 studies. Alternatively, such differences could partly be due to
methodological aspects, i.e., determination of FCRL expression at
mRNA level in our study as compared to protein analysis per-
formed by Li et al. More comparative studies need to be per-
formed to clarify this issue.
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